Pharming requests for listing NASDAQ

The dutch biotech company Pharming requested today the SEC for her listing on the NASDAQ. It's unclear how many shares Pharming wants to place.

For this year the company, located in Leiden revenue will be around 183,99 million euros. This is according to the average of the analysts' estimates. This is slightly more than 2019's revenue of 169,02 million euros.

Historical revenues and results Pharming plus estimates 2020

Pharming

The analysts expect for 2020 a net profit of 41 million euros. According to most of the analysts the company will have a profit per share for this book year of 6 cent. The price-earnings-ratio equals 16,83.

For this year analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies equals a moderate 0,05 percent.

Most recent target prices around 2 euros

Jefferies & Co., First Berlin and Stifel recently provided recommendations for the stock.

Pharming 's market value equals around 628,96 million . The Pharming stock was the past 12 months quite unstable. Since last November the stock is 26 percent lower. This year the stock price moved between 1 and 2 euro.

Historical stock prices Pharming

Click here for dividend Pharming. At 10.43 the stock trades 7,26 percent higher at 1,01 euros.

Analist.nl Nieuwsdienst: +31 084-0032-842
nieuws@analist.nl

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.